Second Enhanced Control of Hypertension and Thrombectomy Stroke Study (ENCHANTED2)

  • STATUS
    Recruiting
  • End date
    Feb 28, 2023
  • participants needed
    2236
  • sponsor
    The George Institute for Global Health, China
Updated on 25 January 2021

Summary

ENCHANTED2 is an international, multicenter, prospective, randomised, open, blinded end-point assessed (PROBE) trial, to assess different approaches to manage blood pressure (BP) in acute ischemic stroke (AIS) patients who have undergone mechanical thrombectomy (MT). There are two nested substudies evaluating different approaches to secondary prevention in this high-risk stroke population.

Description

Objectives: To determine the effectiveness of more intensive BP lowering target (<120 mmHg) compared to higher BP management target (140-180mmHg) on functional outcome in patients with successful recanalization post-MT for AIS due to large vessel occlusion (LVO).

Inclusion Criteria:

  1. Age 18 years;
  2. Diagnosis of AIS with LVO confirmed by brain imaging;
  3. To receive MT <24 hours after AIS onset according to local guidelines;
  4. Successful recanalization (TICI score 2b) after MT;
  5. Sustained systolic BP 140 mmHg (defined as 2 successive readings <10 mins) within 3 hours after recanalization;
  6. Provide written informed consent (or approved surrogate).

Exclusion Criteria:

  1. Unlikely to potentially benefit from therapy (e.g. advanced dementia) or very high likelihood of death within 24 hours post-MT, judged by responsible treating clinician;
  2. Other medical illness that interferes with outcome assessments and follow-up (e.g. known significant pre-stroke disability (mRS scores 3-5), advance cancer and renal failure);
  3. Definite indication/contraindication to different intensities of BP lowering treatment;
  4. Specific contraindications to any of the BP agents to be used (eg, patients who are hypersensitive (allergic) to any of the ingredients);
  5. Patients with aortic isthmus stenosis and arteriovenous shunt (exception: patients with haemodynamically inactive dialysis shunt);
  6. Women who are lactating;
  7. Currently participating in another trial which would interfere with outcome assessments.

Outcome Measures Primary outcome: functional recovery, defined as a shift (improvement) in scores on the modified Rankin scale (mRS) at 90 days.

Secondary outcomes: any intracranial haemorrhage (ICH), symptomatic intracerebral haemorrhage (sICH), early neurological deterioration, imaging assessment (e.g. infarct size, edema volume), death, disability, HRQoL, duration of hospitalization, residence; and health service use for calculation of resources and costs.

Randomisation and intervention: Randomisation is via a central internet-based system, stratified by site, time from symptom onset to recanalization (<6, 6 hours), baseline neurological impairment on the National Institutes for Health Stroke Scale (NIHSS <17 vs 17), to ensure balance in key prognostic factors.

Intensive BP lowering group: to commence intravenous BP lowering therapy immediately after randomization, with systolic BP target (<120 mmHg) achieved within 1 hour, and maintained for at least 72 hours (or hospital discharge if earlier).

Control group: to receive guideline-recommended BP control strategy to maintain BP level 140-180 mmHg after MT procedure, but BP lowering treatment given only for BP 150 mmHg to achieve target 140 mmHg.

Substudies: Patients enrolled in main study can also be randomised into 2 substudies according to separate eligibility criteria. Both are pilot studies embedded in main trial to recruit as many patients to inform sample size estimates for a further main study.

Substudy #1: Timing of anticoagulation Objective: To determine the effectiveness of early initiation of anticoagulation (at Day 42 of stroke onset) compared with late initiation (at Day 122) on a composite outcome of recurrent AIS, sICH, systemic embolism and/or death within 90 days in patients with AF-related AIS due to LVO who receive MT. Randomisation (allocation 1:1 ratio) via same system as main study and stratified by site and randomisation of BP intervention. Randomised patients will be allocated to either early group of initiating OAC therapy at Day 42 day of stroke onset, or late group of initiating OAC therapy at Day 122 of stroke onset. Primary outcome: composite of recurrent AIS, sICH, systemic embolism and/or vascular death within 90 days after randomisation.

Substudy #2: Duration of dual antiplatelet therapy (DAPT):

Objective: To determine the effectiveness of short duration of DAPT (<6 weeks) compared with standard duration (3 months or more) on recurrence rate within 12 months in patients with AIS due to large artery atherosclerosis (LAA) who are eligible for DAPT post-MT. Randomisation (allocation 1:1 ratio) will be done via the same system as the main study and stratified by site and randomisation of BP intervention. Randomised patients will be allocated to either short duration group of receiving DAPT (aspirin 100 mg and clopidogrel 75 mg per day) for 6 weeks, or standard duration group receiving DAPT for 3 months. DAPT is started <48 hours post-randomization, and maintained changed to antiplatelet monotherapy (aspirin or clopidogrel) thereafter. Primary outcome is new stroke event (AIS or ICH) over 12 months.

Details
Condition Acute Ischemic Stroke
Treatment Intensive BP lowering
Clinical Study IdentifierNCT04140110
SponsorThe George Institute for Global Health, China
Last Modified on25 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have Acute Ischemic Stroke?
Do you have any of these conditions: Do you have Acute Ischemic Stroke??
Age 18 years; Diagnosis of AIS with LVO confirmed by brain imaging; To receive
MT <24 hours after AIS onset according to local guidelines; Successful
recanalization (TICI score 2b) after MT; Sustained systolic BP 140 mmHg
(defined as 2 successive readings <10 mins) within 3 hours after
recanalization; Provide written informed consent (or approved surrogate)

Exclusion Criteria

Unlikely to potentially benefit from therapy (e.g. advanced dementia) or very
high likelihood of death within 24 hours post-MT, judged by responsible
treating clinician; Other medical illness that interferes with outcome
assessments and follow-up (e.g. known significant pre-stroke disability (mRS
scores 3-5), advance cancer and renal failure); Definite
indication/contraindication to different intensities of BP lowering treatment
Specific contraindications to any of the BP agents to be used (eg, patients
who are hypersensitive (allergic) to any of the ingredients); Patients with
aortic isthmus stenosis and arteriovenous shunt (exception: patients with
haemodynamically inactive dialysis shunt); Women who are lactating; Currently
participating in another trial which would interfere with outcome assessments
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note